¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • submucosal tumor
    Á¡¸·¹ØÁ¾¾ç, Á¡¸·ÇÏÁ¾¾ç
  • sebaceous tumor
    ÇÇÁö»ùÁ¾¾ç, ±â¸§»ùÁ¾¾ç
  • Sertoli-Leydig cell tumor
    ¼¼¸£Å縮¶óÀ̵ðÈ÷Á¾¾ç
  • sex cord-stromal tumor
    ¼º²ö±âÁúÁ¾¾ç, ¼º»è±âÁúÁ¾¾ç
  • smooth muscle tumor
    ÆòȰ±ÙÁ¾¾ç
  • virilizing tumor
    ³²¼ºÈ­Á¾¾ç
  • Wilms¡¯ tumor
    ºô¸§½ºÁ¾¾ç
  • acceptable daily dose
    ÀÏÀÏÇã¿ë·®
  • average dose
    1. Æò±Õ¿ë·® 2. Æò±Õ¼±·®
  • air dose
    °ø±â¼±·®
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • biologically effective dose
    »ý¹°ÇÐÀûÀ¯È¿¼±·®
  • booster dose
    1. Ãß°¡¿ë·® 2. Ãß°¡Á¢Á¾·®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • submucosal tumor
    Á¡¸·¹ØÁ¾¾ç
  • trophoblastic tumor
    ¿µ¾ç¸·Á¾¾ç
  • Wilms' tumor
    Àª¸§ÁîÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • tumor regeneration
    Á¾¾çÀç»ý
  • sebaceous tumor
    ÇÇÁö»ùÁ¾¾ç
  • sex cord-stromal tumor
    (¢¡stromal tumor) ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • smooth muscle tumor
    ÆòȰ±ÙÁ¾¾ç
  • solid tumor
    °íÇüÁ¾¾ç
  • solid-cystic tumor
    °íü³¶¼ºÁ¾¾ç
  • stromal tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • tumor stain
    Á¾¾çÁ¶¿µ
  • tumor cell survival
    Á¾¾ç¼¼Æ÷»ýÁ¸
  • tumor
    Á¾¾ç
  • teratodermoid tumor
    ±âÇüÀ¯ÇÇÁ¾
  • teratoid tumor
    ±âÇüÁ¾
  • tridermic tumor
    »ï¹è¿±Á¾¾ç
  • trophoblastic tumor
    ¿µ¾ç¸·Á¾¾ç
  • virilizing tumor
    ³²¼ºÈ­Á¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • reacting dose
    ¹ÝÀÀ·®(ÚãëëåÖ).
  • reference dose
    ±âÁؼ±·®
  • relative dose
    ºñ±³ Á¶»ç·®
  • Chinese hamster ovary tumor cell
    Áß±¹ÇÔ½ºÅÍ ³­¼Ò¼¼Æ÷, CHO¼¼Æ÷
  • Dermoid tumor
    À¯ÇÇÁ¾
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
  • Leydig cell tumor
    ·¹À̵ðÈ÷¼¼Æ÷Á¾¾ç
  • Schwann cell tumor
    ½´¹Ý¼¼Æ÷Á¾¾ç
  • TNF => tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
  • Warthins tumor
    ¿Í¸£Æ¾ Á¾¾ç
  • Warthins tumor => adenolymphoma
    ¼±¸²ÇÁÁ¾
  • Wilms tumor
    Àª¸§Á¾¾ç
  • acinic cell tumor
    ¼±¹æ¼¼Æ÷Á¾(¡­á¬øàðþ)
  • acoustic tumor
    û½Å°æÁ¾¾ç
  • adenomatoid tumor
    ¼±¾çÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • desensitizing dose
    Å»°¨ÀÛ·®(÷­ÊõíÂåÖ)
  • desensitizing dose
    Å»°¨ÀÛ·®(÷­ÊõíÂåÖ).
  • dosage/dose
    »ç¿ë·®, Åõ¿©·®.
  • dose
    ¼±·®
  • dose calculation
    ¼±·®°è»ê
  • dose calibration
    ¼±·®ÃøÁ¤ , ¼±·®º¸Á¤
  • dose commitment
    ¼±·®¿¹Å¹
  • dose conversion factor
    ¼±·®º¯È¯°è¼ö
  • dose costraint
    ¼±·®±¸¼ÓÄ¡
  • dose distribution
    ¼±·®ºÐÆ÷
  • dose equivalent
    ¼±·®´ç·®
  • dose limiting factor
    ¼±·®ÇѵµÀÎÀÚ, ¼±·®Á¦ÇÑÀÎÀÚ
  • dose limits (limitation)
    ¼±·®Çѵµ, ¼±·®Á¦ÇÑ
  • dose modifying factor
    ¼±·®¼ö½Ä°è¼ö
  • dose profile
    ¼±·®Ãø¸éµµ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • superior sulcus tumor
    »ó±¸Á¾¾ç
  • supratentorial tumor
    õ¸·»óÁ¾¾ç
  • teratodermoid tumor
    ±âÇüÀ¯ÇÇÁ¾
  • teratoid tumor
    ±âÇü¾çÁ¾¾ç
  • TNM [=Tumor-Lymphnode-Metastasis] classification
    TNMºÐ·ù ¡ìÁ¾¾ç, ¸²ÇÁÀý, ÀüÀ̵éÀ» Ç¥ÁØÀ¸·Î ÇÏ´Â ¾Ç¼ºÁ¾¾çÀÇ ºÐ·ù¹ý¡í
  • trophoblastic tumor
    ¿µ¾ç¸·Á¾¾ç
  • tumor
    Á¾¾ç, Á¾Ã¢
  • tumor cell
    Á¾¾ç¼¼Æ÷
  • tumor shadow
    Á¾¾çÀ½¿µ
  • tumor stain
    Á¾¾ç¿°»ö, Á¾¾çÁ¶¿µ
  • tumor vessel
    Á¾¾çÇ÷°ü
  • vanishing tumor
    Àϰú¼ºÁ¾¾ç»óÀ½¿µ, Àϰú¼º¿±°£Èä¼öÀú·ù(»ó)
  • Warthin's tumor
    ¿Í¸£Æ¾Á¾¾ç
  • Wilms' tumor
    Àª¸§Á¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ADD acceptable daily dose; adduction; adenosine deaminase; attentional deficit disorder; average daily d...
DED date of expected delivery; defined exposure dose; delayed erythema dose
ED early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff...
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
IAD inactivating dose; instructional advance directive; internal absorbed dose
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
DR Dose-ratios
D-R Dose-response
ED50 Effective Dose
ED50 Effective Dose 50
EDE Effective Dose Equivalent
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • minimum dose
    ÃÖ¼Ò·®
  • minimum hemolytic dose
    ÃÖ¼Ò ¿ëÇ÷·®
  • minimum inhibitory dose
    ÃÖ¼Ò ¾ïÁ¦·®
  • minimum reacting dose
    ÃÖ¼Ò ¹ÝÀÀ·®
  • optimal dose
    ÃÖÀû·®, ÀûÁ¤·®
  • oral dose
    ±¸°­ ¿ë·®
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
  • permissible dose
    Çã¿ë·®
  • radiation dose
    ¼±·®
    ¹°ÁúÀ̳ª Á¶Á÷ ¶Ç´Â Àü½Å ¹× ±¹ºÎ µîÀÌ ¹ÞÀº ¹æ»ç¼±ÀÇ ¾ç. Á¶»ç ½Ã°£ ÁßÀÇ ¹æ»ç¼± ¿¡³ÊÁöÀÇ Èí¼ö·®¿¡ ÇØ´çÇÑ´Ù.
  • skin dose
    ÇǺΠ¼±·®
  • therapeutic dose
    Ä¡·á·®, Ä¡·á ¿ë·®
  • total dose
    Àü·®, ÃѼ±·®
  • acoustic tumor
    û½Å°æ Á¾¾ç
    Á¦ 8 ½Å°æ¿¡¼­ »ý±ä ¾ç¼º Á¾¾ç.
  • ACTH-secreting tumor
    ACTH-ºÐºñ Á¾¾ç
    µ¿ÀǾî=corticotro
  • adenomatoid tumor
    ¼± Á¾¾ç Á¾¾ç, À¯¼±Á¾ Á¾¾ç
    ¼ºÀå ¼Óµµ°¡ ´À¸° ÀÛÀº °áÀýÇüÀÇ ¾ç¼º Á¾¾çÀ̳ª ¶§·Î´Â ¼ö cm±îÁö µÉ ¼ö ÀÖ´Ù. ÀÌ Á¾¾çÀº ºÎ°íȯ Á¾¾ç Áß °¡Àå ÈçÇÏ¸ç ¿©ÀÚ¿¡¼­µµ Àڱà ¶Ç´Â ¼ö¶õ°üÀÇ À帷Ãþ¿¡ ¹ß»ýÇÒ ¼ö ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
tissue culture infectious dose The quantity of a cytopathogenic agent, such as a virus, that will produce a cytopathic effect in 50% of the cultures inoculated.
(05 Mar 2000)
tolerance dose The largest dose of a remedy that can be accepted without the production of injurious symptoms.
(05 Mar 2000)
equianalgesic dose The qualitative ratio between actual milligram potency of comparable analgesics required to achieve the equivalent therapeutic effect.
(05 Mar 2000)
equivalent dose In radiation protection, the absorbed dose averaged over a tissue or organ and weighted for the quality of the radiation of interest. The unit of equivalent dose is the sievert.
(05 Mar 2000)
erythema dose The minimum amount of X-rays or other form of radiation sufficient to produce erythema; historically, this dose was indicated by the Sabouraud meter as the B tint, the Holzknecht as 5(5H), the Hampson as 4, and the Kienbock as 10.
(05 Mar 2000)
exit dose The exposure dose of radiation leaving a body opposite the portal of entry.
(05 Mar 2000)
exposure dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
unit dose Occurring in or using a single dose, seen as a standard of measurement.
(18 Nov 1997)
usual dose This is the typical oral dose (all inhalational, suppository or injectables will be specified) given for a particular clinical situation. In most cases, the dose prescribed by your physician will be influenced by many factors including patient age, general health, health history, pregnancy, breast feeding, allergic history, weight and the specific disorder or disease that is being treated. Geriatric patients may be more sensitive to the usual dosage listed here. Pay close attention to the medication strength (in milligrams or grams) listed on the medication container. Caution: Dosage interval may vary with extended-release or Slow-Release preparations.
(27 Sep 1997)
fractional dose A definite fraction of a full dose; given repeatedly at short intervals so that the full dose is taken within a specified period, usually one day.
Synonym: fractional dose.
(05 Mar 2000)
L+ dose The limes tod dose of diphtheria toxin, i.e., the smallest amount of toxin that, when mixed with one unit of antitoxin and injected subcutaneously into a 250-g guinea pig, results in death of the animal within 96 hours (based on the average in a series); on theoretical grounds, one might expect that the difference between the L+ and L0 dose's would be identical to 1 MLD, but this is not so in actual practice; with various toxic filtrates, the difference may range from several to more than 100 MLD's, indicating that the toxin-antitoxin combination is not a firm chemical union that occurs in constant proportions.
(05 Mar 2000)
lethal dose <pharmacology> The amount, or dosage, of a toxin necessary to cause death.
(16 Mar 1998)
lethal dose 50 <pharmacology> The amount, or dosage, of a toxin necessary to kill 50% of the experimental subjects.
(16 Mar 1998)
Lf dose The limes flocculation dose of diphtheria toxin, i.e., the smallest amount of toxin that, when mixed with one unit of antitoxin, yields the most rapid flocculation in the Ramon test (in vitro); in general, the Lf dose is slightly less than the Lr dose.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á